Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- Bidard, F.-C.
- Kaklamani, V.G.
- Neven, P.
- Streich, G.
- Montero, A.J.
- Forget, F.
- Mouret-Reynier, M.-A.
- Sohn, J.H.
- Taylor, D.
- Harnden, K.K.
- Khong, H.
- Kocsis, J.
- Dalenc, F.
- Dillon, P.M.
- Babu, S.
- Waters, S.
- Deleu, I.
- García Sáenz, J.A.
- Bria, E.
- Cazzaniga, M.
- Lu, J.
- Aftimos, P.
- Cortés, J.
- Liu, S.
- Tonini, G.
- Laurent, D.
- Habboubi, N.
- Conlan, M.G.
- Bardia, A.
- Show all authors +
Journal:
Journal of Clinical Oncology
ISSN: 1527-7755, 0732-183X
Year of publication: 2022
Volume: 32
Type: Article